Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0YM2K
|
|||
| Drug Name |
Atezolizumab
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Non-small-cell lung cancer [ICD-11: 2C25] | Approved | [1] | |
| Bladder cancer [ICD-11: 2C94; ICD-9: 188] | Phase 3 | [2] | ||
| Breast cancer [ICD-11: 2C60-2C65] | Phase 3 | [2] | ||
| Hepatocellular carcinoma [ICD-11: 2C12.02; ICD-10: C22.0; ICD-9: 155] | Phase 3 | [2] | ||
| Ovarian cancer [ICD-11: 2C73; ICD-10: C56; ICD-9: 183] | Phase 3 | [2] | ||
| Prostate cancer [ICD-11: 2C82.0; ICD-10: C61; ICD-9: 185] | Phase 3 | [2] | ||
| Renal cell carcinoma [ICD-11: 2C90; ICD-10: C64; ICD-9: 189] | Phase 3 | [2] | ||
| Small-cell lung cancer [ICD-11: 2C25.Y; ICD-9: 162.9] | Phase 3 | [2] | ||
| Squamous cell carcinoma [ICD-11: 2B60-2D01] | Phase 3 | [2] | ||
| Urothelial carcinoma [ICD-11: 2C92.0] | Phase 3 | [2] | ||
| Acute myeloid leukaemia [ICD-11: 2A60] | Phase 1 | [2] | ||
| Colorectal cancer [ICD-11: 2B91.Z] | Phase 1 | [2] | ||
| Follicular lymphoma [ICD-11: 2A80] | Phase 1 | [2] | ||
| Gastric adenocarcinoma [ICD-11: 2B72; ICD-9: 151] | Phase 1 | [2] | ||
| Haematological malignancy [ICD-11: 2B33.Y] | Phase 1 | [2] | ||
| Melanoma [ICD-11: 2C30; ICD-9: 172] | Phase 1 | [3] | ||
| Multiple myeloma [ICD-11: 2A83; ICD-10: C90.0] | Phase 1 | [2] | ||
| Myelodysplastic syndrome [ICD-11: 2A37; ICD-9: 238.7] | Phase 1 | [2] | ||
| Pancreatic cancer [ICD-11: 2C10] | Phase 1 | [2] | ||
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1 | [2], [4] | ||
| Bronchioalveolar carcinoma [ICD-11: 2C25.0; ICD-9: 162] | Phase 0 | [5] | ||
| Ulcer [ICD-11: CA02-CB40; ICD-10: K51] | Phase 0 | [5] | ||
| Company |
Genentech South San Francisco, CA
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Programmed cell death 1 ligand 1 (PD-L1) | Target Info | . | [1] |
| KEGG Pathway | Cell adhesion molecules (CAMs) | |||
| Reactome | PD-1 signaling | |||
| WikiPathways | Costimulation by the CD28 family | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 5 | Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.